Cargando…
The tumor suppressor FLCN mediates an alternate mTOR pathway to regulate browning of adipose tissue
Noncanonical mechanistic target of rapamycin (mTOR) pathways remain poorly understood. Mutations in the tumor suppressor folliculin (FLCN) cause Birt-Hogg-Dubé syndrome, a hamartomatous disease marked by mitochondria-rich kidney tumors. FLCN functionally interacts with mTOR and is expressed in most...
Autores principales: | Wada, Shogo, Neinast, Michael, Jang, Cholsoon, Ibrahim, Yasir H., Lee, Gina, Babu, Apoorva, Li, Jian, Hoshino, Atsushi, Rowe, Glenn C., Rhee, James, Martina, José A., Puertollano, Rosa, Blenis, John, Morley, Michael, Baur, Joseph A., Seale, Patrick, Arany, Zoltan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159669/ https://www.ncbi.nlm.nih.gov/pubmed/27913603 http://dx.doi.org/10.1101/gad.287953.116 |
Ejemplares similares
-
Blood and lymphatic systems are segregated by the FLCN tumor suppressor
por: Tai-Nagara, Ikue, et al.
Publicado: (2020) -
AMPK promotes induction of the tumor suppressor FLCN through activation of TFEB independently of mTOR
por: Collodet, Caterina, et al.
Publicado: (2019) -
Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-β signaling
por: Hong, Seung-Beom, et al.
Publicado: (2010) -
Characterization of a splice-site mutation in the tumor suppressor gene FLCN associated with renal cancer
por: Bartram, Malte P., et al.
Publicado: (2017) -
Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression
por: Wu, Mingsong, et al.
Publicado: (2015)